Senior Director, New Ventures, China
Han Dai is Senior Director of New Ventures, China, for Johnson & Johnson Innovation, Asia Pacific. In this role, he is responsible for developing and implementing the Innovation strategy in China, creating a deep and credible network with innovators and entrepreneurs in the regional healthcare ecosystem. He also focuses on the identification and evaluation of external opportunities in China, supporting negotiations and playing a critical role in the management of academic and industrial collaborations that have the potential to impact the Johnson & Johnson portfolio for global markets.
Han has 20+ years of experience in the pharma/biotech/healthcare sector. Prior to joining Johnson & Johnson Innovation, he has worked at BeiGene where he led a discovery biology team, built innovative drug discovery platforms, identified and validated new targets, and supported search & evaluation and due diligence. Before returning to China, he also had a strong track record in leading discovery, preclinical development, translational research and biomarker studies projects across many therapeutic areas, including oncology, immunology, metabolic diseases, and neuroscience at the GlaxoSmithKline US R&D headquarters.
Han holds a Ph.D. in Molecular Biophysics from the University of Texas Southwestern Medical Center at Dallas as a Frank and Sara McKnight Fellow, and he received his B.S. in Biochemistry from the Department for Intensive Instruction, Nanjing University. He also completed his postdoctoral training at Harvard Medical School and HHMI as a Helen Hay Whitney Fellow.